LB PHARMACEUTICALS INC (LBRX) — Institutional Holders, Q2 2026 (page 2)

115 institutional investment managers reported a LBRX position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $965.3M. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 101 to 115. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.

LBRX 13F holders ranked 101–115 of 115

Institutional investors reporting a position in LB PHARMACEUTICALS INC on SEC Form 13F-HR for Q2 2026, ranked by reported value.
InstitutionValueQoQ
Sterling Capital Management#101 · 274 sh$8.9K-25.5%
State of Wyoming#102 · 198 sh$6.4KNew
GAMMA Investing#103 · 196 sh$6.4K+21.0%
Global Retirement Partners#104 · 189 sh$6.1K—
Aster Capital Management (DIFC) Ltd#105 · 65 sh$2.1KNew
MassMutual Private Wealth & , FSB#106 · 54 sh$1.8K0.0%
Integrated Wealth Concepts#107 · 25 sh$811.00New
WPG Advisers#108 · 18 sh$584.00New
Rossby Financial, LCC#109 · 14 sh$454.00New
SRS Capital Advisors#110 · 11 sh$357.00New
Quarry#111 · 10 sh$325.00New
Caitong International Asset Management , Ltd#112 · 5 sh$162.00New
EverSource Wealth Advisors#113 · 2 sh$65.00-80.0%
Allworth Financial#114 · 1 sh$33.000.0%
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#115 · 16,378 sh—+1473.3%

Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.